Breast cancer is common in females, and accounts for a large proportion of cancer-related cases of mortality.
Introduction
Breast cancer is the most frequently diagnosed malignant tumor in females, accounting for 29% of all new cancer cases among women in 2013, as well as 14% of cancer-related cases of mortality (1, 2) . In recent decades, the breast cancer mortality rate has decreased by >30%, principally due to advances in therapeutic strategies (1, 2) . Further study of breast cancer mechanisms may continue to improve these therapeutic strategies.
MicroRNAs (miRs) are endogenous non-coding RNAs that can negatively mediate gene expression by inhibition of translation or induction of mRNA degradation (3) . Previous studies have revealed that miRs are involved in the regulation of numerous biological processes, including cell proliferation, cell cycle progression, differentiation, apoptosis and motility (4) (5) (6) . Moreover, deregulation of certain miRs can lead to abnormal upregulation or downregulation of oncogenes or tumor suppressor genes (7, 8) . Therefore, miRs also play key roles in tumorigenesis. MiR-203 has previously been found to be associated with the development and progression of breast cancer. For instance, Wang et al found that miR-203 suppressed cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells (9) . Ding et al found that miR-203 inhibited the epithelial-mesenchymal transition and tumor metastasis of breast cancer by inhibition of TGF-β and SNAI2 (10, 11) . However, the underlying mechanism of miR-203 in estrogen-dependent breast cancer remains unclear.
Estrogens, such as steroid hormone estradiol (E2), mediate numerous physiological and pathological processes, including tumorigenesis (12) . For instance, continuous stimulation of the mammary gland by E2 is associated with the development and progression of breast cancer (13) . Estrogen receptor α (ERα) is a member of the nuclear receptor superfamily of transcription factors that act as key mediators of estrogen activity (14, 15) . Moreover, ERα has previously been demonstrated to regulate cell proliferation, differentiation and homeostasis in numerous tissues, and play a critical role in determining a prognosis or therapeutic strategy for breast cancer (16) . ERα has previously been suggested as a potential target for the endocrine-based treatment of breast cancer (17, 18) . However, the regulatory mechanism of ERα in breast cancer has not yet been fully elucidated.
The current study investigated the effect of miR-203 on the malignant phenotypes of ERα-positive breast cancer cells, as well as the underlying mechanism of miR-203. Treatment with E2. MCF-7 cells were treated with 0.1, 1 or 10 mM E2 for 3 h. Subsequently, the rates of cell viability, migration and invasion were evaluated.
MiR-203 inhibits estrogen-induced viability, migration and invasion of estrogen receptor α-positive breast cancer cells
Cell viability analysis. An MTT assay was conducted to analyze MCF-7 cell viability in each group. A total of 5,000 cells were plated into a 96-well plate. After incubation at 37˚C with 5% CO 2 for 12, 24, 48 or 72 h, 20 µl of MTT (5 mg/ml, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added. Cells were incubated at 37˚C for a further 4 h, then 150 µl of dimethyl sulfoxide (DMSO) was added. After reacting for 10 min at room temperature, formazan production was detected by measurement of optical density (OD) at 570 nm using a Multiskan FC enzyme immunoassay analyzer (Thermo Fisher Scientific, Inc.).
Cell migration assay. A wound healing assay was conducted to evaluate the cell migration capacity of MCF-7 cells in each group. MCF-7 cells were cultured to full confluence. Wounds of ~1 mm width were created with a plastic scriber, and cells were washed with PBS once. After being cultured at 37˚C with 5% CO 2 for 48 h, MCF-7 cells were observed under an inverted microscope (Olympus Corporation, Tokyo, Japan).
Cell invasion assay. Cell invasion assays were performed using Transwell chambers pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). A cell suspension containing 5x10 5 cells/ml was prepared in DMEM, and 300 µl cell suspension was added into the upper chamber, while 500 µl DMEM with 10% FBS was added into the lower chamber. After incubation at 37˚C with 5% CO 2 for 24 h, cells that did not invade through the pores were wiped out using a cotton-tipped swab. Then, 20 µl MTT was added, cells were incubated at 37˚C for 4 h, and 150 µl DMSO was added. After reacting for 10 min at room temperature, formazan production was detected by measurement of OD at 570 nm using a Multiskan FC enzyme immunoassay analyzer (Thermo Fisher Scientific, Inc.).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. Total RNA of MCF-7 cells in each group was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), in accordance with the manufacturer's instructions. For detection of miR-203 expression, 1 µg total RNA was reverse transcribed using the miScript Reverse Transcription Kit (Qiagen, Inc., Valencia, CA, USA), in accordance with the manufacturer's instructions. Then, qPCR was conducted using the miScript SYBR Green PCR kit (Qiagen, Inc.) on an ABI 7500 PCR machine (Applied Biosystems; Thermo Fisher Scientific, Inc.). Primers were provided by Guangzhou Fulengen Co., Ltd. (cat. no. HmiRQP9001; Guangzhou, China; sequences not provided). The reaction conditions were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 10 sec and 60˚C for 30 sec. The relative expression of miRNA was normalized against that of U6 using the 2 -∆∆Cq method (20) .
Cell transfection. MCF-7 cells were transfected with miR-203 mimics (Thermo Fisher Scientific, Inc.) or scrambled miRNA as a nega tive control (miR-NC) (Thermo Fisher Scientific, Inc.) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols.
Western blot analysis. MCF-7 cells were lysed and protein was isolated using radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Inc.). The concentration of protein was quantified using a bicinchoninic acid protein assay kit (Santa Cruz Biotechnology, Inc., Dallas, TX USA). For western blot analysis, 60 µg protein was separated using 12% SDS-PAGE gels, and transferred onto a polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific, Inc.). The PVDF membrane was blocked in 5% nonfat dried milk in PBS with Tween (Sigma-Aldrich; Merck KGaA) for 3 h at room temperature. The membrane was then incubated with mouse anti-ERα monoclonal antibody (1:200; ab66102; Abcam, Cambridge, MA, USA), or mouse anti-GAPDH monoclonal antibody (1:400; ab8245; Abcam) at room temperature for 3 h. The membrane was washed with PBS three times, then incubated with goat anti-mouse horseradish peroxidase-conjugated secondary antibody (1:20,000; ab6789; Abcam) for 1 h at room temperature. Chemiluminescent detection was performed with an Enhanced Chemiluminescence kit (Pierce; Thermo Fisher Scientific, Inc.). Protein expression was analyzed using Image-Pro Plus software 6.0 (Media Cybernetics, Inc., Rockville, MD, USA), according to the manufacturer's protocol. GAPDH was used as an internal control.
Bioinformatics analysis. Targetscan 3.1 online software (www.targetscan.org) was used to predict the potential targets of miR-203, according to the manufacturer's protocol.
Luciferase reporter assay. A luciferase reporter assay was conducted to elucidate the targeting relationship between miR-203 and ERα in MCF-7 cells. The wild-type (WT) or mutant type (MUT) 3' untranslated region (UTR) of ERα mRNA was inserted downstream of the luciferase reporter gene in a pMIR-REPORT vector. MCF-7 cells were then co-transfected with pRL-SV40 (Promega Corporation, Madison, WI, USA) expressing Renilla luciferase, miR-203 mimics or scrambled miRNA (miR-NC), and pMIR-REPORT vectors containing the WT or MUT ERα 3'-UTR, then incubated at 37˚C with 5% CO 2 for 48 h. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega Corporation), in accordance with the manufacturer's instructions.
Statistical analysis. Data are expressed as the mean ± standard deviation of three independent experiments. One-way analysis of variance was conducted using SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA) in order to analyze the differences among groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Effect of E2 treatment on the viability, migration and invasion of ERα-positive breast cancer MCF-7 cells. MCF-7 cells are ERα-positive. In the present study, MCF-7 cells were treated with E2 (0.1, 1 or 10 mM). At 3 h, an MTT assay was performed to determine the cell viability. As shown in Fig. 1A , treatment with 10 mM E2 significantly increased MCF-7 cell viability compared to the control group (P<0.05). Moreover, at 72 h, treatment with 10 mM E2 increased cell viability significantly more than treatment with 1 mM E2 (P<0.05), suggesting that the effect of E2 on MCF-7 cell viability was dose-dependent. On this basis, a dosage of 10 mM E2 was used to treat MCF-7 cells in the cell migration and invasion assays. As shown in Fig. 1B and C, treatment with E2 significantly increased the migration and invasion rates of MCF-7 cells, as compared with the control group (P<0.05). These results indicated that E2 enhanced the malignant phenotypes of breast cancer MCF-7 cells. It was proposed that this activity may be via binding to ERα and activating ERα-mediated signaling pathways.
Effect of E2 treatment on miR-203 levels in MCF-7 cells.
The effect of E2 treatment on the expression levels of miR-203 in MCF-7 cells was investigated. RT-qPCR data showed that treatment with 1 or 10 mM E2 led to a significant decrease in the expression level of miR-203 in MCF-7 cells, as compared with the control group (P<0.05; Fig. 2 ). Furthermore, it was found that treatment with 10 mM E2 decreased miR-203 expression significantly more than treatment with 1 mM E2 (P<0.05), and treatment with 1 mM E2 decreased miR-203 expression significantly more than treatment with 0.1 mM E2 (P<0.05), suggesting that the effects of E2 on miR-203 expression were dose-dependent. These data indicate that miR-203 is negatively mediated by E2 in ERα-positive breast cancer cells.
Effect of miR-203 overexpression on E2-induced MCF-7 cell viability, migration and invasion.
In order to investigate the role of miR-203 in ERα-positive breast cancer cells further, MCF-7 cells were transfected with miR-203 mimic or miR-NC as a negative control. After transfection for 48 h, RT-qPCR was performed to examine the miR-203 levels in each group. As shown in Fig. 3A , transfection with miR-203 mimic resulted in a significant increase in miR-203 levels in MCF-7 cells, as compared with the control group (P<0.05), while transfection with miR-NC had no visible effect. MCF-7 cells were then treated with 10 mM E2 for 3 h, and the cell viability, migration and invasion rates were analyzed. As shown in Fig. 3B , the cell viability of MCF-7 cells was significantly decreased after overexpression of miR-203 at 24, 48 or 72 h (P<0.05). Furthermore, the migration and invasion rates were significantly lower in MCF-7 cell transfected with miR-203 mimics, as compared with the control group (P<0.05; Fig. 3C and D). These data suggest that miR-203 serves a suppressive function in the E2-induced viability, migration and invasion of ERα-positive breast cancer cells.
MiR-203 negatively mediates ERα protein levels via binding
directly to its mRNA in MCF-7 cells. Bioinformatics analysis predicted that ERα was a direct target of miR-203. Therefore, it was investigated whether miR-203 had an effect on the protein expression of ERα in MCF-7 cells. Western blot analysis results indicated that transfection with miR-203 mimics significantly decreased the protein expression of ERα in MCF-7 cells, as compared with the control group (P<0.05; Fig. 4A ), while transfection with miR-NC showed no visible effect on the ERα levels in MCF-7 cells. These data suggested that miR-203 negatively mediated the protein levels of ERα in breast cancer cells. In order to elucidate the relationship between miR-203 and ERα, a luciferase reporter assay was conducted. A WT or MUT 3'UTR of ERα mRNA (Fig. 4B ) was inserted downstream of the luciferase reporter gene in a pMIR-REPORT vector (Fig. 4C ). The luciferase activity in MCF-7 cells co-transfected with miR-203 mimic and WT ERα-3'UTR-pMIR-REPORT reporter vector was significantly decreased compared with the control group (P<0.05; Fig. 4D ). However, there was no visible effect on the luciferase activity in MCF-7 cells co-transfected with miR-203 mimic and MUT-ERα-3'UTR-pMIR-REPORT reporter vector compared with the control group, indicating that ERα is a direct target of miR-203. These findings indicated that miR-203 negatively mediated the protein levels of ERα by directly binding to its mRNA in breast cancer cells.
Effect of miR-203 overexpression on ERα expression in
ERα-positive breast cancer tissue samples. The expression levels of miR-203 in ERα-positive breast cancer tissue samples as well as in their matched normal adjacent tissue samples were evaluated using RT-qPCR. As indicated in Fig. 5A , the expression levels of miR-203 were significantly decreased in breast cancer tissues compared to their normal adjacent tissues (P<0.05). Furthermore, the correlation between miR-203 and ERα expression levels was evaluated in breast cancer tissues. As shown in Fig. 5B , the expression levels of miR-203 were inversely correlated with ERα expression levels in ERα-positive breast cancer tissue samples (R 2 =0.6519). These results indicated that miR-203 may be involved in the development of ERα-positive breast cancer via negatively mediating the expression of ERα.
Discussion
The present study investigated the effect of miR-203 on the malignant phenotypes of ERα-positive breast cancer cells. It was found that treatment with E2 significantly increased the viability, migration and invasion of ERα-positive breast cancer MCF-7 cells, accompanied by decreased levels of miR-203. Overexpression of miR-203 suppressed the E2-induced upregulation of MCF-7 cell viability, migration and invasion. Further investigation revealed that miR-203 negatively media ted the protein expression of ERα via directly binding to its mRNA in MCF-7 cells. In addition, it was indicated that miR-203 was significantly downregulated in ERα-positive breast cancer tissues, and its expression levels were inversely correlated with ERα levels.
It has been well established that sustained exposure to E2 increases the risk of breast cancer (21) , and inhibition of E2-mediated signaling has been suggested as a key strategy for the treatment of estrogen-dependent breast cancer (22, 23) . In the present study, it was demonstrated that treatment with E2 significantly enhanced the viability, migration and invasion of ERα-positive breast cancer cells. Previously, Munagala et al used the August-Copenhagen Irish rat model, which develops mammary tumors by E2 treatment, to investigate changes in miRs during the process of mammary tumorigenesis, and found that several miRs, such as miR-375, -206, -182, -122, -127 and -183, were dysregulated throughout the mammary carcinogenesis process (24) . These findings suggest that certain miRs are involved in the development of breast cancer. Indeed, some miRs have been demonstrated to act as oncogenes or tumor suppressors in breast cancer (25) (26) (27) . For instance, miR-29b was previously found to be significantly downregulated in breast cancer, associated with poorer disease-free survival, and was suggested to be an independent prognostic factor for overall survival (28) . MiR-373 has been found to drive the epithelial-to-mesenchymal transition and metastasis in breast cancer via the miR-373-TXNIP-HIF1α-TWIST signaling axis (29) . MiR-206 was reported to inhibit the proliferation and invasion of breast cancer cells by targeting Cx43 (30) . Thus, expanding the understanding of miRs in breast cancer may contribute to the development of effective therapeutic strategies for breast cancer.
Recently, miR-203 has been implicated in numerous types of human cancer, such as gastric carcinoma (31), hepatocellular carcinoma (32) and lung cancer (33) . It was reported to be significantly downregulated in gastric carcinoma and to promote cancer metastasis via inhibition of Slug (31) . MiR-203 also suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting ADAM9 and long non-coding RNA HULC (32). Chen et al (33) found that miR-203 inhibited the proliferation and invasion of non-small cell lung cancer cells by targeting Bmi1. In addition, miR-203 suppresses proliferation and induces apoptosis of human oral cancer cells (34) . In the present study, it was found that treatment with E2 induced a significant decrease in miR-203 levels in breast cancer cells, suggesting that it may be involved in E2-mediated malignant progression of breast cancer MCF-7 cells. Yu et al also reported that E2 significantly induced bcl-2, cyclin D1 and survivin expression by suppressing the levels of miR-16, miR-143 and miR-203 in MCF-7 cells (35) , consistent with the current findings.
Furthermore, it has been demonstrated that the function of ERα impacts breast tumor growth as well as breast cancer patient response to endocrine therapy (36, 37) . In addition, the functions of ERα, including chromatin interaction, co-regulator recruitment and gene expression, are regulated by phosphorylation through various kinase signaling pathways, such as mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase/protein kinase B, which have been found to be associated with breast cancer growth and metastasis (21, 38, 39) . In the present study, it was found that miR-203 negatively mediated the protein expression of ERα via direct binding to the 3'UTR of its mRNA. Moreover, it was found that decreased levels of miR-203 were inversely correlated with the expression levels of ERα in primary ERα-positive breast cancer tissues. These results suggest that ERα is involved in the suppressive effects of miR-203 on the malignant phenotypes of breast cancer cells.
In conclusion, the current study reveals a novel molecular mechanism of miR-203 in ERα-positive breast cancer. MiR-203 inhibits the viability, migration and invasion of estrogen-dependent breast cancer cells via direct inhibition of the protein levels of ERα. These findings suggest that miR-203 is a potential candidate for the treatment of ERα-positive breast cancer.
